GET DAILY SIGNALSTravere Therapeutics (TVTX) Q3 2026 Earnings Preview: Tracking FILSPARI Momentum
Key Takeaways
- Travere Therapeutics is scheduled to report third quarter 2026 results on Monday, November 2, 2026, after the U.S. market close.
- Wall Street consensus points to quarterly revenue of roughly $196 million, with earnings per share (EPS) estimates clustered near $0.05.
- Sales of FILSPARI (sparsentan), the company's lead therapy for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), remain the single most important metric investors will watch.
- In the prior quarter, FILSPARI sales surged 96% year over year to $141.1 million, and management reaffirmed a combined peak sales target exceeding $3 billion.
- The company ended its most recent quarter with approximately $489.2 million in cash and securities, supporting continued investment in its pipeline.
Why This Earnings Release Matters
Travere Therapeutics has shifted from a loss-making rare-disease developer into a commercial-stage company driven primarily by FILSPARI. Second quarter 2026 sales reached $169.6 million, reflecting a 48% year-over-year increase. This upcoming report will show whether that pace can hold as the FSGS launch develops and IgAN demand keeps building. For investors, the numbers provide a key update on commercial progress, pricing trends, and the route toward profitability, making it a focal point on the biotech calendar this fall. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Consensus Expectations for Q3
Analysts project third quarter 2026 revenue near $196 million, continuing the expansion from FILSPARI in both approved indications. EPS estimates center around $0.05 per share, although forecasts differ and the company often reports both GAAP and non-GAAP results that can vary. The key focus is the growth path for FILSPARI net product sales, which hit $141.1 million in the second quarter, up 96% year over year. Management has kept its combined peak sales target above $3 billion. Investors will also monitor gross-to-net discounts, which the company expects in the mid-20% range for 2026, along with operating expense control and updates on the Phase III pegtibatinase program and civorebrutinib pipeline.
Market Sentiment and Analyst Views
Heading into the report, sentiment is cautiously optimistic with some short-term caution. Shares have eased from post-second-quarter peaks as investors assess whether FILSPARI growth can continue amid ongoing GAAP losses and an elevated forward price-to-earnings multiple for a commercial-stage biotech. Analysts at Piper Sandler and Wells Fargo maintain Buy ratings with price targets of $68 and $80. Historical post-earnings moves have been mixed, so any shortfall on FILSPARI sales or a change in peak sales guidance could lead to notable volatility given the valuation.
What to Watch Going Forward
Beyond the headline figures, several areas will shape the outlook in coming quarters. The first is the staying power of FILSPARI growth in both indications, with IgAN as the main driver and FSGS showing uptake that has outpaced early IgAN patterns. New patient starts, discontinuation rates, and reimbursement trends will help gauge progress toward the multi-billion-dollar peak sales goal. Second is pricing and margins, where management has guided gross-to-net discounts toward the mid-20% range for 2026. Third are pipeline updates, including Phase III results for pegtibatinase expected in the second half of 2027 and civorebrutinib advancing toward a U.S. IND filing. Finally, balance sheet strength remains relevant, with roughly $489 million in cash and securities and a refinanced debt structure providing runway, though spending discipline will be monitored as the company moves toward sustained profitability.
Using AI Tools for Biotech Research
In my experience, tools like Tickeron’s AI-powered platforms help streamline the process of comparing companies in the biotech sector and spotting patterns around earnings events. One that I turn to regularly for filtering ideas based on fundamentals, technical signals, and industry trends is the AI Screener, which lets users scan thousands of stocks efficiently without manual effort. It has become a useful part of my routine when preparing for reports like this one from TVTX.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TVTX's Stochastic Oscillator is staying in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TVTX's RSI Oscillator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for TVTX just turned positive on October 22, 2026. Looking at past instances where TVTX's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in 217 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TVTX as a result. In 87 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 10-day moving average for TVTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for TVTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TVTX's P/B Ratio (238.095) is very high in comparison to the industry average of (3.151). P/E Ratio (17.370) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (5.690) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (439.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops pharmaceutical products
Industry Biotechnology
Advertisement